IART:NGS-Integra LifeSciences Holdings Corporation (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 24.81

Change

-0.64 (-2.51)%

Market Cap

USD 3.08B

Volume

1.11M

Analyst Target

USD 58.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Integra Lifesciences Holdings Corp is engaged in development, manufacturing, and marketing of product lines from its technology for applications ranging from burn and deep tissue wounds to repair of dura mater in the brain to repair of nerve and tendon.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-1.81 (-2.43%)

USD 27.48B
PODD Insulet Corporation

-6.04 (-2.20%)

USD 16.52B
BRKR Bruker Corporation

-0.10 (-0.18%)

USD 8.98B
MASI Masimo Corporation

+0.83 (+0.52%)

USD 7.71B
PRCT Procept Biorobotics Corp

-3.30 (-3.45%)

USD 4.99B
AXNX Axonics Modulation Technologie..

-0.04 (-0.06%)

USD 3.60B
TMDX TransMedics Group Inc

+1.32 (+1.44%)

USD 2.89B
NARI Inari Medical Inc

-0.53 (-1.03%)

USD 2.85B
LIVN LivaNova PLC

+0.58 (+1.09%)

USD 2.80B
UFPT UFP Technologies Inc

-28.76 (-8.37%)

USD 2.65B

ETFs Containing IART

XHE SPDR® S&P Health Care Eq.. 2.52 % 0.35 %

-1.55 (-1.68%)

USD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.03% 40% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.03% 40% F 20% F
Trailing 12 Months  
Capital Gain -36.71% 32% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.71% 32% F 20% F
Trailing 5 Years  
Capital Gain -57.08% 48% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.08% 48% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -9.00% 28% F 22% F
Dividend Return -9.00% 28% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.75% 85% B 57% F
Risk Adjusted Return -27.46% 27% F 21% F
Market Capitalization 3.08B 86% B+ 76% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 52.10 29% 17%
Price/Book Ratio 0.97 77% 73%
Price / Cash Flow Ratio 10.59 14% 27%
Price/Free Cash Flow Ratio 14.86 17% 25%
Management Effectiveness  
Return on Equity 1.47% 88% 61%
Return on Invested Capital 5.16% 81% 67%
Return on Assets 3.51% 90% 80%
Debt to Equity Ratio 93.52% 34% 26%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector